CLINICAL_TRIALS
trial_result
· 2026-04-02
Clinical Trial Update: A Study of TAS3351 in NSCLC Patients With EGFRmt [Phase 1]
Summary
Phase 1 study of TAS3351 in EGFR-mutant non-small cell lung cancer was terminated, with results posted on 2026-04-02.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Taiho Oncology, Inc. | Conditions: Non-Small Cell Lung Cancer | Phase 1 | Status: TERMINATED | Results posted: 2026-04-02